Table 1A.
Baseline characteristics: demographics and previous treatment.
| n = 43 (%) | |
|---|---|
| AGE | |
| Median | 63,5 |
| Range | 41–76 |
| SEX | |
| Male | 40 (93) |
| Female | 3 (7) |
| ORIGIN | |
| Bladder | 34 (79) |
| Other | 9 (21) |
| SURGERY | |
| Not received | 18 (42) |
| Cistectomy | 22 (51) |
| Nephroureterectomy | 3 (7) |
| PERIOPERATIVE TREATMENT | |
| Not received | 32 (74) |
| Neoadjuvant | 0 (0) |
| Adjuvant | 11 (26) |
| CT only | 7 (16) |
| RT only | 2 (5) |
| CT + RT | 2 (5) |
| FIRST-LINE REGIMEN | |
| CBDCA | 24 (56) |
| CDDP | 16 (37) |
| GEM/PTX | 3 (7) |
| VINFLUNINE LINE | |
| II line | 35 (81) |
| III line | 6 (14) |
| IV line | 2 (5) |
| TIME TO RELAPSE/PROGRESSION AFTER THE PRIOR CHEMOTHERAPY | |
| ≤ 6 months | 32 (74) |
| >6 months | 11 (26) |
CT, Chemotherapy; RT, Radiotherapy; CBDCA, Carboplatin; CDDP, Cisplatin; GEM/PTX, Gemcitabine/Paclitaxel.